Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.

Christer Frode AasJørn Henrik VoldSvetlana SkurtveitIngvild OdsbuFatemeh ChalabianlooAaron G LimKjell Arne JohanssonLars Thore Fadnes

Published in: Substance abuse treatment, prevention, and policy (2020)

An increase in DAA treatment and HCV treatment uptake was observed among Swedish and Norwegian OAT patients whilst introducing new direct-acting antiviral treatment regimens. However, more than two thirds of the OAT population in Norway and Sweden were untreated at the beginning of 2018. A further scale-up is crucial in order to control and eliminate the HCV endemic among OAT patients.

Keyphrases

end stage renal disease
chronic kidney disease
stem cells
human immunodeficiency virus
replacement therapy
hiv infected
patient reported
adverse drug
electronic health record